Drug Trial Radar · NCT02322229
Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion
Last checked: Nov 20, 2026Latest source record: Aug 21, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
62
Actual
Start
May 26, 2015
Primary completion
Dec 11, 2015
Study completion May 9, 2016
Sponsor
- Lead sponsor
- Alcon ResearchIndustry
- Sponsor type
- Industry
- First posted
- Dec 23, 2014
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to observe the anatomical and functional outcomes of ocriplasmin (JETREA™®) over a 6-month period.
Conditions
- Vitreomacular Traction
- Vitreomacular Adhesion
Interventions
Ocriplasmin 0.125 mg in a 0.1 mL volumeDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects With Non-surgical Resolution of Focal VMT/sVMA at Day 28, as Determined by Central Reading Center (CRC) Spectral Domain Optical Coherence Tomography (SD-OCT) EvaluationTime frame: Day 28
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Contact Alcon Laboratories (Australia) for Trial Locations
New South Wales, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.